There is no doubt that Virginia is open for business to the life sciences industry. Over the past several years, the state has seen significant growth in pocket ecosystems across the land, particularly in areas like Charlottesville, Richmond, and Blacksburg.
Montgomery County is well known for many transformative firsts in life sciences. First to sequence the human genome; first gene therapy for sickle cell, first cell therapy for COVID-19 — and that’s just the start.* Montgomery County is an epicenter for translating knowledge into life-changing treatment and cures, with gene and cell therapies representing some of the most promising advancements in human health.
ATCC, the world’s premier biological materials management and standards organization, today announced that it has entered into an agreement with QIAGEN, a recognized leader in bioinformatics solutions, to provide them with sequencing data from its collection of cell lines, and animal and human biological materials. QIAGEN Digital Insights, the bioinformatics unit of QIAGEN, will establish a database from this information to develop and deliver high-value digital biology content for the biotechnology and pharmaceutical industries, enabling the use of authenticated biological data sets to uncover new disease pathways and discover novel therapeutic targets.
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today marked World TB Day by announcing its QuantiFERON blood test has been used to screen patients for tuberculosis (TB) infection more than 100 million times since its launch – an achievement that cements its status as the gold standard in the fight against this contagious and often deadly disease.
In 2019, Ellume announced its global partnership with QIAGEN to make testing more accessible by developing a new version of the QuantiFERON test, called QIAreach™ QFT. This technology, which is about half the size of a laptop and battery-operated, combines Ellume’s ultrasensitive digital detection technology with a complete testing workflow that can test up to eight samples simultaneously. Further, it can detect active infections as well as latent infections before progression to illness and further spread. This early detection can allow for the correct measures and treatments to be applied and increase the effectiveness of TB programs.
QIAGEN reaches milestone with its kits used to process more than three billion biological samples to date
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that the number of biological samples processed with consumables kits has passed the three billion mark – a record that underlines its leadership in enabling molecular laboratories to gain valuable insights in research, combatting diseases and forensics.
QIAGEN receives U.S. FDA emergency use authorization for rapid portable test that can analyze over 30 samples per hour for SARS-CoV-2 antigen
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced it has received emergency use authorization (EUA) from the U.S. Food and Drug Administration (FDA) for its QIAreach® SARS CoV-2 Antigen Test, which is designed for environments that require a high volume of fast and accurate test results.
QIAGEN launches the Workflow Configurator to help life science researchers simplify and optimize their laboratory experiments
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of the Workflow Configurator, enabling researchers in the life sciences to easily and quickly find the best solutions to optimize their experiments.
QIAGEN forms strategic alliance with Sysmex Corporation for global cancer companion diagnostics development and commercialization using NGS and Plasma-Safe-SeqS technology
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced a global strategic alliance with Japan’s Sysmex Corporation (Tokyo Stock Exchange, First Section [Ticker Code: 6869]) for the development and commercialization of cancer companion diagnostics, which will leverage both QIAGEN’s leadership in this field and Sysmex’s Plasma-Safe-SeqS technology for next generation sequencing (NGS).
QIAGEN Launches Dedicated CRISPR Products for Rapid and Simplified Analysis of Gene-Editing Experiments
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of QIAprep& CRISPR Kit and CRISPR Q-Primer Solutions that allow researchers to analyze edited genetic material with unparalleled speed and efficiency to determine how their interventions have changed the function of the DNA sequence in question.